 <h1>Jentadueto XR Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>linagliptin / metformin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about linagliptin / metformin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Jentadueto XR.</p><h2>In Summary</h2><p><b>Common side effects of Jentadueto XR include:</b> lactic acidosis and hypoglycemia. <b>Other side effects include:</b> decreased vitamin b12 serum concentrate.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to linagliptin/metformin: oral tablet, oral tablet extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet; Tablet, Extended Release)</p><p>Lactic acidosis can occur due to metformin accumulation during treatment with linagliptin / metformin hydrochloride, and case reports of death, hypothermia, hypotension, and resistant bradyarrhythmias have been reported. The risk of lactic acidosis is increased with renal impairment, concomitant cationic drugs (eg, topiramate), age 65 years or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Onset is often subtle with symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities include elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally greater than 5 mcg/mL. If lactic acidosis is suspected, immediately discontinue therapy, hospitalize patient, and promptly start hemodialysis.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, linagliptin / metformin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking linagliptin / metformin:</p><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>increased hunger</li>
<li>loss of consciousness</li>
<li>nausea</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>constipation</li>
<li>darkened urine</li>
<li>fainting spells</li>
<li>fever</li>
<li>indigestion</li>
<li>irregular heartbeat</li>
<li>large, hard skin blisters</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>severe joint pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of linagliptin / metformin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>excess air or gas in the stomach or intestines</li>
<li>feeling of fullness</li>
<li>heartburn</li>
<li>lack or loss of strength</li>
<li>muscle aches</li>
<li>passing gas</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Cough</li>
<li>decreased appetite</li>
<li>difficulty with moving</li>
<li>flaking and falling off of the skin</li>
<li>hives or welts, itching, or skin rash</li>
<li>muscle aching or cramping</li>
<li>muscle pains or stiffness</li>
<li>redness of the skin</li>
<li>swollen joints</li>
</ul><p>
<!-- end oral tablet, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to linagliptin / metformin: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported adverse events included nasopharyngitis and diarrhea.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia was more commonly reported in patients receiving the combination linagliptin / metformin plus a sulfonylurea compared with those receiving metformin plus a sulfonylurea (22.9% vs 14.8%; n=792).<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p>
<p><b>Frequency not reported</b>: Hypoglycemia</p>
<p></p>
<p>Linagliptin:</p>
<p><b>Common</b> (1% to 10%): Hypertriglyceridemia, hyperlipidemia, weight increased</p>
<p></p>
<p>Metformin: </p>
<p><b>Very rare</b> (less than 0.01%): Lactic acidosis, vitamin B12 deficiency<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Linagliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Decreased appetite, diarrhea, nausea, vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood amylase</p>
<p><b>Postmarketing reports</b>: Mouth ulceration</p>
<p></p>
<p>Linagliptin:</p>
<p><b>Common</b> (1% to 10%): Constipation, diarrhea </p>
<p><b>Frequency not reported</b>: Pancreatitis</p>
<p> </p>
<p>Metformin:</p>
<p><b>Very common</b> (10% or more): Diarrhea, nausea, vomiting, abdominal pain, decreased appetite</p>
<p><b>Common</b> (1% to 10%): Constipation </p>
<p><b>Frequency not reported</b>: Flatulence, indigestion<sup>[Ref]</sup></p><p>Gastrointestinal events such as nausea, vomiting, diarrhea, decreased appetite, and abdominal pain occur most frequently during initiation of therapy and resolve spontaneously in most cases.  </p>
<p>During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea).  Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin.  Postmarketing reports of acute pancreatitis, including fatalities, have been received.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with linagliptin.  These reactions have occurred within the first 3 months, with some occurring after the first dose.<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p>
<p><b>Rare</b> (less than 0.1%): Drug hypersensitivity</p>
<p></p>
<p>Linagliptin</p>
<p><b>Postmarketing reports</b>: Serious hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Linagliptin-Metformin</p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis (6.3%),</p>
<p><b>Uncommon</b> (0.1% to 1%): Cough</p>
<p></p>
<p>Linagliptin </p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis, cough</p>
<p></p>
<p>Metformin</p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus </p>
<p><b>Postmarketing reports</b>: Angioedema, urticaria, rash</p>
<p></p>
<p>Metformin:</p>
<p><b>Very rare</b> (less than 0.01%): Skin reactions such as erythema, pruritus, and urticaria</p>
<p></p>
<p>Dipeptidyl peptidase-4 inhibitors:</p>
<p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Metformin</p>
<p><b>Very rare</b> (less than 0.01%): Megaloblastic anemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Metformin: </p>
<p><b>Very rare</b> (less than 0.01%): Hepatitis, liver function test abnormalities<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Linagliptin:</p>
<p><b>Frequency not reported</b>: Myalgia, arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Taste disturbance<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Linagliptin:</p>
<p><b>Common</b> (1% to 10%): Urinary tract infection,<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Linagliptin: </p>
<p><b>Common</b> (1% to 10%): Headache</p>
<p></p>
<p>Metformin: </p>
<p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Jentadueto (linagliptin-metformin)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Jentadueto XR (linagliptin / metformin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: antidiabetic combinations</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jentadueto XR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Jentadueto</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to linagliptin / metformin: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported adverse events included nasopharyngitis and diarrhea.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia was more commonly reported in patients receiving the combination linagliptin / metformin plus a sulfonylurea compared with those receiving metformin plus a sulfonylurea (22.9% vs 14.8%; n=792).<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p><p><b>Frequency not reported</b>: Hypoglycemia</p><p></p><p>Linagliptin:</p><p><b>Common</b> (1% to 10%): Hypertriglyceridemia, hyperlipidemia, weight increased</p><p></p><p>Metformin: </p><p><b>Very rare</b> (less than 0.01%): Lactic acidosis, vitamin B12 deficiency<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Linagliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Decreased appetite, diarrhea, nausea, vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood amylase</p><p><b>Postmarketing reports</b>: Mouth ulceration</p><p></p><p>Linagliptin:</p><p><b>Common</b> (1% to 10%): Constipation, diarrhea </p><p><b>Frequency not reported</b>: Pancreatitis</p><p> </p><p>Metformin:</p><p><b>Very common</b> (10% or more): Diarrhea, nausea, vomiting, abdominal pain, decreased appetite</p><p><b>Common</b> (1% to 10%): Constipation </p><p><b>Frequency not reported</b>: Flatulence, indigestion<sup>[Ref]</sup></p><p>Gastrointestinal events such as nausea, vomiting, diarrhea, decreased appetite, and abdominal pain occur most frequently during initiation of therapy and resolve spontaneously in most cases.  </p><p>During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea).  Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin.  Postmarketing reports of acute pancreatitis, including fatalities, have been received.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with linagliptin.  These reactions have occurred within the first 3 months, with some occurring after the first dose.<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p><p><b>Rare</b> (less than 0.1%): Drug hypersensitivity</p><p></p><p>Linagliptin</p><p><b>Postmarketing reports</b>: Serious hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Linagliptin-Metformin</p><p><b>Common</b> (1% to 10%): Nasopharyngitis (6.3%),</p><p><b>Uncommon</b> (0.1% to 1%): Cough</p><p></p><p>Linagliptin </p><p><b>Common</b> (1% to 10%): Nasopharyngitis, cough</p><p></p><p>Metformin</p><p><b>Common</b> (1% to 10%): Nasopharyngitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><p>Linagliptin-Metformin:</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus </p><p><b>Postmarketing reports</b>: Angioedema, urticaria, rash</p><p></p><p>Metformin:</p><p><b>Very rare</b> (less than 0.01%): Skin reactions such as erythema, pruritus, and urticaria</p><p></p><p>Dipeptidyl peptidase-4 inhibitors:</p><p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Metformin</p><p><b>Very rare</b> (less than 0.01%): Megaloblastic anemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Metformin: </p><p><b>Very rare</b> (less than 0.01%): Hepatitis, liver function test abnormalities<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Linagliptin:</p><p><b>Frequency not reported</b>: Myalgia, arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Metformin:</p><p><b>Common</b> (1% to 10%): Taste disturbance<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Linagliptin:</p><p><b>Common</b> (1% to 10%): Urinary tract infection,<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Linagliptin: </p><p><b>Common</b> (1% to 10%): Headache</p><p></p><p>Metformin: </p><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Jentadueto (linagliptin-metformin)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p><h2>More about Jentadueto XR (linagliptin / metformin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: antidiabetic combinations</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jentadueto XR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>